Clopidogrel intermediate metabolizer

March 2017: The FDA-approved label for clopidogrel (Plavix) was recently updated (September 2016) and warns that patients who are CYP2C19 poor metabolizers may have diminished effectiveness CYP2C19 intermediate and poor metabolizers who receive clopidogrel experience reduced platelet inhibition and increased risk for major adverse cardiovascular and cerebrovascular events. Like many medicines, how well the medicine works and side effects are different from person to person

2024-03-19
    Mildronate order original in sydney